Equities Analysts Issue Forecasts for REGN FY2026 Earnings

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) - Cantor Fitzgerald cut their FY2026 earnings estimates for Regeneron Pharmaceuticals in a research report issued on Wednesday, July 9th. Cantor Fitzgerald analyst C. Gould now anticipates that the biopharmaceutical company will post earnings of $26.04 per share for the year, down from their previous forecast of $26.24. Cantor Fitzgerald has a "Overweight" rating and a $695.00 price objective on the stock. The consensus estimate for Regeneron Pharmaceuticals' current full-year earnings is $35.92 per share.

A number of other research firms have also recently commented on REGN. Citigroup reduced their target price on shares of Regeneron Pharmaceuticals from $700.00 to $650.00 and set a "buy" rating on the stock in a research report on Monday, June 2nd. Robert W. Baird lowered their target price on Regeneron Pharmaceuticals from $759.00 to $652.00 and set a "neutral" rating for the company in a research note on Friday, April 25th. JPMorgan Chase & Co. lowered their target price on Regeneron Pharmaceuticals from $950.00 to $800.00 and set an "overweight" rating for the company in a research note on Monday, June 9th. Guggenheim reiterated a "buy" rating on shares of Regeneron Pharmaceuticals in a research note on Friday, May 30th. Finally, Morgan Stanley dropped their target price on shares of Regeneron Pharmaceuticals from $755.00 to $754.00 and set an "overweight" rating for the company in a research report on Thursday. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating, sixteen have given a buy rating and three have given a strong buy rating to the company. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $823.54.

Regeneron Pharmaceuticals Stock Up 1.0%

NASDAQ REGN traded up $5.57 on Thursday, reaching $565.33. The company had a trading volume of 465,053 shares, compared to its average volume of 912,391. The firm has a market capitalization of $61.04 billion, a PE ratio of 14.38, a P/E/G ratio of 2.06 and a beta of 0.33. Regeneron Pharmaceuticals has a 1 year low of $476.49 and a 1 year high of $1,211.20. The firm has a 50-day moving average of $545.98 and a 200-day moving average of $621.52. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.93 and a quick ratio of 4.03.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last released its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $8.22 EPS for the quarter, missing the consensus estimate of $8.83 by ($0.61). Regeneron Pharmaceuticals had a net margin of 31.94% and a return on equity of 15.27%. The company had revenue of $3.03 billion during the quarter, compared to analysts' expectations of $3.40 billion. During the same period last year, the business earned $9.55 earnings per share. The company's revenue for the quarter was down 3.7% compared to the same quarter last year.

Hedge Funds Weigh In On Regeneron Pharmaceuticals

Several large investors have recently made changes to their positions in REGN. CX Institutional lifted its stake in Regeneron Pharmaceuticals by 7.9% during the second quarter. CX Institutional now owns 302 shares of the biopharmaceutical company's stock valued at $159,000 after purchasing an additional 22 shares during the last quarter. Diversified Trust Co increased its holdings in shares of Regeneron Pharmaceuticals by 35.3% in the second quarter. Diversified Trust Co now owns 3,889 shares of the biopharmaceutical company's stock valued at $2,042,000 after buying an additional 1,015 shares in the last quarter. Kingstone Capital Partners Texas LLC bought a new position in shares of Regeneron Pharmaceuticals in the second quarter valued at $40,736,000. Grove Bank & Trust increased its holdings in shares of Regeneron Pharmaceuticals by 36.7% in the second quarter. Grove Bank & Trust now owns 1,107 shares of the biopharmaceutical company's stock valued at $581,000 after buying an additional 297 shares in the last quarter. Finally, Baker Tilly Wealth Management LLC increased its holdings in shares of Regeneron Pharmaceuticals by 10.8% in the second quarter. Baker Tilly Wealth Management LLC now owns 1,280 shares of the biopharmaceutical company's stock valued at $672,000 after buying an additional 125 shares in the last quarter. Institutional investors own 83.31% of the company's stock.

Regeneron Pharmaceuticals Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, June 6th. Investors of record on Tuesday, May 20th were issued a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a yield of 0.62%. The ex-dividend date of this dividend was Tuesday, May 20th. Regeneron Pharmaceuticals's payout ratio is currently 8.96%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.